Inovio Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Inovio said the FDA approved Voceric, formerly known as INO3107, under the Accelerated Approval Program as a non-surgical treatment to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).
- In RRP001, 32 adult patients who had 2 to 8 surgeries in the year before treatment received 4 doses over 9 weeks; the FDA's efficacy analysis focused on 26 patients with 3 or more prior-year surgeries, among whom 27% had no surgeries in the 12 months after the dosing window.
- The company said the vast majority of patients experienced a 50 to 100% reduction in surgery in year 1, with durable responses and continued clinical improvement in year 2; management also cited durability into the third year.
- Voceric was generally well tolerated in the clinical study, with mostly low-grade treatment-emergent adverse events, including injection site pain and fatigue, and the majority being grade 1.
- Third-quarter 2026 operating expenses were $19.8 million, compared with $21.2 million in the third quarter of 2025.
- Third-quarter 2026 net loss was $49.2 million, or $0.50 per share basic and dilutive, compared with a net loss of $45.5 million, or $0.87 per share basic and dilutive, in the third quarter of 2025; the increase was primarily driven by a $26.9 million non-cash loss on fair value adjustment related to warrant liabilities, compared with $22.5 million in the same period in 2025.
- Inovio had $48.4 million in cash, cash equivalents, and short-term investments at the end of the third quarter of 2026 and received approximately $80.5 million in net proceeds from an equity offering, plus $10.9 million from warrant exercises after September 30th, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Third Quarter 2026 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on Tuesday, November 10, 2026. I would now like to turn the conference over to Jennie Willson. Thank you. Please go ahead.
Good afternoon, and thank you for joining the Inovio Third Quarter 2026 Financial Results Conference Call. Joining me on today's call are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Mike Sumner, Chief Medical Officer, Steve Egge, Chief Commercial Officer, and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended September 30, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment.
Before we begin, I'd like to remind you that we will be making certain forward-looking statements as outlined in this slide, including but not limited to our ability to obtain and maintain regulatory approval of our product candidates, the design and timing of our planned confirmatory study, the potential benefits of VOCERYQ and its potential to become a product preferred by patients and their physicians, our commercial launch plans and strategy, including anticipated cash runway, cash burn, and timing of product revenues, and our plans to expand VOCERYQ into additional indications and geographies to advance our broader pipeline. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially.
We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed verbally by the company or in this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com, and a replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's President and CEO, Dr. Jackie Shea.
Good afternoon, and thank you to everyone for joining. I'd like to start today's call by highlighting the recent FDA approval of VOCERYQ, formerly known as INO-3107, under the Accelerated Approval Program as a new non-surgical treatment option to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, or RRP. In the press release it issued, the FDA stated that VOCERYQ was a groundbreaking therapy and that its approval represented a meaningful scientific breakthrough by offering patients a plasmid DNA-based immunotherapy that harnesses the body's own immune system to fight the underlying cause of RRP. The accelerated approval for VOCERYQ and the broad indication included in its label for adults with RRP are an acknowledgment of the significant unmet need for non-surgical treatment options for RRP and the potential therapeutic benefit that VOCERYQ can provide.
We believe it has the potential to transform the treatment paradigm for this disease by delivering what we understand matters most to patients, reducing the need for surgery. This is a pivotal moment for RRP patients who have faced a relentless cycle of surgery for far too long with limited treatment options, and for Inovio, as we move forward into an exciting new chapter as a commercial-stage company. Going forward, our primary focus will be maximizing the opportunity we see for VOCERYQ and executing our commercial launch with the goal of establishing it as the preferred first-line treatment for adults with RRP. To support those efforts, we recently completed an equity offering that provided approximately $80.5 million in net proceeds.
These proceeds, together with our existing cash resources and subsequent warrant exercise proceeds, are expected to support operations into late fourth quarter 2027, past the launch of VOCERYQ, without taking potential expected product revenues into account. The approval of our first commercial product validates our platform and confirms our belief in the potential of our pipeline candidates to help patients suffering from other diseases. While our initial focus is on the successful launch of VOCERYQ within our broad adult indication, we will also be looking to expand the potential of VOCERYQ to serve additional indications within the RRP marketplace, both here in the U.S. and internationally. We will also continue to prioritize partnerships to efficiently advance our clinical-stage candidates and look to establish new partnerships to advance promising earlier-stage candidates in our pipeline.
This is truly a transformative time for Inovio and for DNA medicine, and we are excited about the significant opportunities ahead. I'll now turn it over to Mike Sumner, our Chief Medical Officer, to provide a few more details on the approval, product label, and supporting clinical data.
Mike? Thank you, Jackie. The approval of VOCERYQ is exciting on many fronts.
It's Inovio's first approved product, the first FDA-approved plasmid DNA-based immunotherapy. Most importantly, an innovative and much-needed new treatment option for adults with RRP. I'd like to spend some time today providing a few highlights from the approval of VOCERYQ and its broad adult indication. VOCERYQ was evaluated in RRP001, a multi-site clinical study designed to assess what matters most to patients, reduction in surgery. The study followed 32 adult patients who had two to eight surgeries in the year prior to treatment. Patients had visible papillomas surgically removed before receiving their first dose of VOCERYQ. Patients then received four doses over a nine-week period. The primary efficacy endpoint was a reduction in surgery following dosing initiation. In this trial, we counted all surgeries after the first dose against the efficacy endpoint.
We also conducted study RRP002, a retrospective assessment of treatment effect up to three years after initial dosing in patients who had participated in the 001 study. The full clinical data from these studies were published in 2025 in Nature Communications and in The Laryngoscope, the top journal for the specialists who treat RRP. An additional analysis of data was also recently published in The Laryngoscope, supporting the ability of VOCERYQ to generate an immune response that linked to durable clinical benefit over the second and third years following initial treatment. These publications highlight the meaningful therapeutic benefit of VOCERYQ, with the vast majority of patients experiencing a 50%-100% reduction in surgery in year one, with durable responses and continued clinical improvement in year two.
The FDA's efficacy evaluation for Accelerated Approval focused specifically on the first-year treatment effect for patients who required three or more surgeries in the 12 months prior to treatment. For those 26 patients, the median number of surgeries in the 12 months prior to the first dose was 4.5, which included the surgical debulking required immediately prior to treatment. FDA's efficacy analysis started at the end of the dosing window at week nine. In the following 12 months, 27% of the patients achieved complete response, as defined by not requiring any surgeries to manage their disease. As a reminder, this response was achieved without conducting any scoping or surgery during the dosing window. Patients going from needing three or more surgeries a year to needing zero surgeries following treatment would not be expected as part of the natural history of the disease.
In terms of safety, VOCERYQ was found in the clinical study to be well tolerated, with study participants experiencing mostly low-grade treatment-emergent adverse events such as injection site pain and fatigue, with the majority being grade 1. This slide lists the most common adverse reactions occurring in greater than or equal to 5% of patients, as described in the prescribing information. Of note, because VOCERYQ is a drug-device combination product composed of our plasmid DNA-based drug with delivery by our CELLECTRA device, this safety profile represents the combination product. For this approval, the safety data were further supported by data from prior clinical trials of VGX-3100, a HPV 16 and 18-related disease program, which included over 1,100 administrations and a placebo control. Delivery with our proprietary CELLECTRA device is well characterized and has also been shown in additional clinical studies to be well tolerated.
It is also important to point out here that reducing the need for surgery, both as part of or following treatment, is an important consideration for patients. Every surgery matters because every individual surgery comes with significant risk. Finally, I'd like to share a brief overview of our future confirmatory study. As VOCERYQ has received an Accelerated Approval, continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory study. We expect to submit a draft protocol for this study before year-end, with the goal of aligning with the FDA on a final protocol by mid-2027. We have agreed with the agency that the study should enroll at least 50 adult and pediatric patients with RRP requiring three or more surgical interventions in the 12 months prior to treatment with VOCERYQ.
Subject to further regulatory feedback, we expect the study to evaluate the number of surgical interventions required over at least three years following completion of treatment, and compare this to an appropriate external control group or scientifically justified threshold. We may also explore continued treatment in patients without a sustained complete response as part of the study. I will now turn it over to Steve Egge, our Chief Commercial Officer, for an overview of our commercial launch plans.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
